Ying Cheng
Changzhi University(CN)Hainan Normal University(CN)Sun Yat-sen University(CN)Xinjiang Agricultural University(CN)Beijing Technology and Business University(CN)Yunnan University(CN)Changzhi Medical College(CN)Peking University(CN)Wenzhou Medical University(CN)Suzhou University of Science and Technology(CN)Nanjing University of Science and Technology(CN)Jilin Province Tumor Hospital(CN)Suzhou Municipal Hospital(CN)Peking University First Hospital(CN)Sun Yat-sen University Cancer Center(CN)National Chin-Yi University of Technology(TW)Beihang University(CN)Nanjing Medical University(CN)Xinjiang University(CN)Air Force Medical University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Colorectal Cancer Treatments and Studies, Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer(2017)5,101 cited
- → Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer(2018)3,583 cited
- → Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial(2019)3,270 cited
- → Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC(2019)2,707 cited
- → Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial(2017)1,186 cited
- → Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction